Jelmyto Demonstrates Significant Recurrence-Free Survival Rate at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer

Your email address will not be published. Required fields are marked *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Comment *